U.S. Markets open in 2 hrs 57 mins
  • S&P Futures

    4,253.25
    +21.75 (+0.51%)
     
  • Dow Futures

    33,953.00
    +194.00 (+0.57%)
     
  • Nasdaq Futures

    14,349.50
    +86.50 (+0.61%)
     
  • Russell 2000 Futures

    2,316.80
    +16.50 (+0.72%)
     
  • Crude Oil

    73.14
    +0.06 (+0.08%)
     
  • Gold

    1,782.20
    -1.20 (-0.07%)
     
  • Silver

    26.08
    -0.03 (-0.10%)
     
  • EUR/USD

    1.1950
    +0.0017 (+0.1434%)
     
  • 10-Yr Bond

    1.4870
    0.0000 (0.00%)
     
  • Vix

    15.60
    -1.06 (-6.36%)
     
  • GBP/USD

    1.3971
    +0.0007 (+0.0531%)
     
  • USD/JPY

    110.8120
    -0.1500 (-0.1352%)
     
  • BTC-USD

    33,355.35
    -660.93 (-1.94%)
     
  • CMC Crypto 200

    805.28
    -4.91 (-0.61%)
     
  • FTSE 100

    7,093.07
    +19.01 (+0.27%)
     
  • Nikkei 225

    28,875.23
    +0.34 (+0.00%)
     

Omnicell's (OMCL) 2025 Roadmap Impressive, Pandemic Woe Stays

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
  • Oops!
    Something went wrong.
    Please try again later.

On Apr 1, we issued an updated research report on Omnicell, Inc. OMCL. The company announced its strategy of expanding into new markets. However, a tough competitive landscape is a dampener.

Over the past six months, Omnicell’s shares have outperformed the industry it belongs to. The stock has gained 75.8% compared with the industry’s 14.6% rise.

Omnicell’s optimism about the gradual resumption of elective surgeries and some on-site sales activities in regions less impacted by the pandemic is encouraging. The company is progressing in autonomous pharmacy by expanding its portfolio and investing in the digital cloud-based platform. On the assumption that its customers have resumed their pre-COVID purchasing patterns, during the fourth-quarter 2020 results, the company provided its product bookings guidance for 2021 .

Omnicell is progressing well with its three-pronged strategy that covers market expansion through delivery of differentiated, innovative solutions; expansion into new markets, primarily outside the United States; and expansion through strategic partnerships and acquisition of new technologies.

Omnicell, Inc. Price

Omnicell, Inc. Price
Omnicell, Inc. Price

Omnicell, Inc. price | Omnicell, Inc. Quote

In 2020, the company expanded its autonomous pharmacy portfolio with the strategic and accretive acquisition of PSG's 340B Link business, now called Omnicell 340B. The company also accelerated shift to cloud-based solutions and tech-enabled services through the launches of Omnicell One and Central Pharmacy Dispensing Services. This year, the company has seen rapid growth in SaaS, subscription software and tech-enabled services bookings.

In terms of its 2025 financial roadmap, Omnicell is targeting 14% to 15% compounded total annual revenue growth rate from 2021 to 2025. Over the same period of time, it is also targeting an expansion of non-GAAP EBITDA margin from 21% in 2021 to 25% by 2025, indicating a margin expansion of approximately 400 basis points. According to the company, its strong position in the market, growing customer base and strategic focus on innovation will help it to achieve these goals.

On the flip side, the coronavirus pandemic has been wreaking havoc on the economy and the impact on Omnicell has been damaging as well. The company noted that it is witnessing significantly lower product bookings as well as slowdown in purchasing decisions by hospitals. The pandemic has impacted the company’s 2020 results with slowdown in product bookings.

Shelter-in-place was enforced throughout the United States and parts of Europe, elective surgeries postponed and hospital systems ramped up to treat COVID-19 patients. As a result, the company’s sales teams had some difficulty engaging with customers on new bookings. Also, some implementations from backlog were delayed as hospitals were consumed with treating COVID-19 patients or were preparing for a potential surge in COVID-19 admissions.

Zacks Rank & Key Picks

Currently, Omnicell carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Haemonetics Corporation HAE, IDEXX Laboratories, Inc. IDXX and Align Technology, Inc. ALGN.

Haemonetics’ long-term earnings growth rate is estimated at 10%. The company presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

IDEXX’s long-term earnings growth rate is estimated at 15.8%. It currently carries a Zacks Rank #2.

Align Technology’s long-term earnings growth rate is estimated at 19.8%. It currently sports a Zacks Rank #1.

Bitcoin, Like the Internet Itself, Could Change Everything

Blockchain and cryptocurrency has sparked one of the most exciting discussion topics of a generation. Some call it the “Internet of Money” and predict it could change the way money works forever. If true, it could do to banks what Netflix did to Blockbuster and Amazon did to Sears. Experts agree we’re still in the early stages of this technology, and as it grows, it will create several investing opportunities.

Zacks’ has just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.

See 3 crypto-related stocks now >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Omnicell, Inc. (OMCL) : Free Stock Analysis Report

Haemonetics Corporation (HAE) : Free Stock Analysis Report

Align Technology, Inc. (ALGN) : Free Stock Analysis Report

IDEXX Laboratories, Inc. (IDXX) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research